Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

2009's Private Biotech Acquisitions Are a Tale of Two Step-Ups

This article was originally published in Start Up

Executive Summary

Not every acquisition of a venture-backed biotech in 2009 was a structured deal that included earn-outs based on clinical or regulatory milestones. But it sure was close. Thirteen private biotechnology companies were acquired in 2009 and of those deals only a few did not include contingent value rights (CVRs).

You may also be interested in...



BioMarin Refreshes Its Pipeline With ZyStor Acquisition

In a deal weighted heavily toward downstream payments, the orphan drug maker gains a compound that could challenge Genzyme in Pompe disease.

BioMarin Refreshes Its Pipeline With ZyStor Acquisition

In a deal weighted heavily toward downstream payments, the orphan drug maker gains a compound that could challenge Genzyme in Pompe disease.

Biotech Backers Learn To Live With Exit-By-Earn-Out

Even as both public investors and pharma companies more vigorously sniff out biopharma opportunities, exits for venture-backed firms remain scarce. Can risk-sharing acquisitions save the day?

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

ID1124690

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel